Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRecursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.52 USD 0.02 ( 0.57%)
Last update at 2026-11-06T21:01:00Z
VOLUME
15335901
Market Cap
1737.52M

Momentum Score

…

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.48
Low
3.65
High
52 Week Price Range
2.77
Low
7.18
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Recursion Pharmaceuticals applies automated, high-throughput cellular imaging and machine learning to discover and develop small molecules and biologics across multiple therapeutic areas. Its growth could be driven by scaling its phenomics dataset and models, advancing internally discovered programs into clinical stages, and generating revenue from collaborations and licensing to advance the pipeline and improve discovery efficiency.
Investors should monitor clinical and regulatory risk, the unproven translation of its platform to approved drugs, high cash burn and financing needs, and intense competition from both AI-driven and traditional drug developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.50
Dividend Yield
-
Revenue TTM
54.86M
Revenue Per Share
0.11
Gross Profit TTM
-392.60M
Debt / Equity
0.07
ROE
-56.58%
Net Debt
-665.33M
ROCE
-48.48%
Diluted EPS TTM
-0.95

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -644.89M -464.79M -332.13M -239.48M -186.48M
Net income -644.76M -463.66M -328.07M -239.42M -178.07M
Selling general administrative 176.59M 178.18M 110.82M 81.60M 57.68M
Selling and marketing expenses - - 10.40M - -
Gross profit -46.27M 13.60M 1.29M -8.59M 10.00M
Reconciled depreciation 83.70M 36.49M 20.06M 11.76M 8.40M
Ebit -643.09M -463.22M -332.03M -257.48M -191.18M
Ebitda -559.38M -426.72M -307.63M -245.73M -182.78M
Depreciation and amortization 83.70M 36.49M 24.40M 11.76M 8.40M
Non operating income net other - - - - -3.70M
Operating income -648.13M -479.00M -350.06M -245.73M -182.78M
Other operating expenses 722.81M 537.84M 393.94M 285.41M 192.78M
Interest expense 1.81M 1.57M 0.10M 0.06M 2.95M
Tax provision -0.14M -1.13M -4.06M - -
Interest income 22.79M 15.76M 18.28M 6.25M 0.07M
Net interest income 20.98M 14.19M 18.19M 6.20M -2.88M
Income tax expense -0.14M -1.13M -4.06M -0.06M -8.40M
Total revenue 74.68M 58.84M 43.88M 39.68M 10.00M
Total operating expenses 601.86M 492.61M 351.35M 237.13M 192.78M
Cost of revenue 120.95M 45.24M 42.59M 48.27M -
Total other income expense net 3.24M 14.22M 17.93M 6.25M -3.70M
Net income from continuing ops -644.76M -463.66M -292.56M -239.48M -186.48M
Net income applicable to common shares - - - -239.48M -186.48M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1474.13M 1448.60M 653.70M 701.29M 610.35M
Intangible assets 309.90M 335.86M 36.44M 1.31M 1.39M
Other current assets 44.90M 70.75M 40.25M 15.87M 7.51M
Total liab 343.26M 413.82M 190.26M 215.48M 67.41M
Total stockholder equity 1130.87M 1034.78M 463.44M 485.81M 542.94M
Deferred long term liab - - - - 4.11M
Other current liab 70.23M 81.87M 46.63M 32.90M 32.33M
Common stock 0.01M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.00M 0.00M 0.00M 0.00M
Retained earnings -2076.00M -1431.28M -967.62M -639.56M -400.08M
Other liab - - - 70.26M 10.78M
Good will 162.16M 148.87M 52.06M 0.80M 0.80M
Other assets - - 0.00M 7.92M 8.72M
Cash 743.29M 594.35M 394.80M 549.91M 285.12M
Total current liabilities 147.71M 187.47M 93.17M 100.27M 46.66M
Current deferred revenue 37.60M 61.77M 36.43M 56.73M 10.00M
Net debt -665.33M -485.86M -344.12M -498.91M -273.64M
Short term debt 21.75M 22.22M 6.16M 6.05M 1.51M
Short long term debt 9.09M 8.43M 0.04M 0.10M 0.09M
Short long term debt total 77.97M 108.49M 50.67M 51.01M 11.48M
Other stockholder equity 3170.14M 2473.70M 1431.06M 1125.36M 332.80M
Property plant equipment - - - 121.45M 64.72M
Total current assets 812.85M 714.27M 438.14M 569.81M 534.72M
Net tangible assets - - - 483.70M 540.75M
Short term investments - - - 0.00M 231.45M
Net receivables 24.65M 49.17M 3.09M 2.75M 9.09M
Long term debt 9.56M 19.02M 1.10M 0.54M 0.63M
Inventory - - -3.09M 1.28M 1.55M
Accounts payable 18.12M 21.61M 3.95M 4.59M 2.82M
Accumulated other comprehensive income 36.72M -7.64M 0.00M - -0.13M
Common stock total equity - - - - 0.00M
Retained earnings total equity - - - - -400.08M
Non currrent assets other 18.79M 8.82M 0.26M 7.92M 8.72M
Non current assets total 661.28M 734.33M 215.56M 131.47M 75.63M
Capital lease obligations 59.31M 81.05M 49.53M 50.37M 10.76M
Long term debt total - - - - 0.63M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -3.81M 260.06M -15.72M 193.25M -231.95M
Change to liabilities - - - 112.09M 14.51M
Total cashflows from investing activities -16.87M 260.06M -10.23M 193.25M -271.74M
Net borrowings -8.43M -4.44M -0.77M -0.09M -12.80M
Total cash from financing activities 521.53M 304.12M 140.13M 154.34M 458.54M
Change to operating activities - - - -7.17M 7.83M
Net income -644.76M -463.66M -328.07M -239.48M -186.48M
Change in cash 150.90M 201.60M -157.69M 263.76M 28.18M
Begin period cash flow 603.02M 401.43M 559.11M 295.35M 267.17M
End period cash flow 753.92M 603.02M 401.43M 559.11M 295.35M
Total cash from operating activities -371.81M -359.17M -287.78M -83.52M -158.61M
Issuance of capital stock 528.86M 300.42M 193.71M 143.71M 462.90M
Depreciation 83.70M 36.49M 24.40M 11.76M 8.40M
Other cashflows from investing activities -6.60M -3.35M -0.60M - -
Change to inventory - - - - 7.83M
Change to account receivables 32.94M -6.07M -7.76M - 0.11M
Sale purchase of stock - - - - 471.34M
Other cashflows from financing activities -3.00M 8.14M 12.81M 10.72M 8.44M
Change to netincome - - - 39.27M 19.77M
Capital expenditures 6.47M 13.70M 11.96M 37.36M 39.80M
Change receivables - - - - 0.11M
Cash flows other operating - - - - -14.93M
Cash and cash equivalents changes - - - - 28.18M
Change in working capital 13.69M -38.00M -44.26M 104.92M -0.31M
Stock based compensation 111.22M 81.69M 53.50M 27.91M 14.84M
Other non cash items 64.34M 24.31M 6.64M 11.37M 4.10M
Free cash flow -378.28M -372.87M -300.33M -120.88M -198.41M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RXRX
Recursion Pharmaceuticals Inc		 0.02
0.57%		 3.52 - - 31.67 2.00 25.30 -5.31
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

41 South Rio Grande Street, Salt Lake City, UT, United States, 84101

385 269 0203

https://www.recursion.com

600

Name Title Year Born
Dr. Christopher C. Gibson Ph.D. Co-Founder, CEO & Director 1983
Ms. Tina Marriott Larson COO & Pres 1975
Dr. Blake C. Borgeson Ph.D. Co-Founder & Director 1982
Dr. Michael Secora Ph.D. Chief Financial Officer 1983
Dr. Shafique Virani M.D. Interim Chief Medical Officer & Chief Bus. Officer 1971
Kevin Leggat VP of Fin. & Accounting NA
Mr. Benjamin Mabey M.S. Chief Technology Officer 1983
Mr. Jared Allenbach Sr. Director of Investor Relations NA
Ms. Louisa Daniels J.D., M.B.A. Chief Legal Officer & Gen. Counsel 1958
Mr. Ryan Kelly Chief Communications Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…